Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars
On May 4, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. He discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).
Click to access part 1, part 2, and part 3 of the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust
ABA Antitrust Plaintiffs' Roundtable 2025
Speaking Engagement
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Corporate Counsel Women, Influence, & Power in Law Conference 2025
Speaking Engagement
Antitrust